328. **MOLECULAR BASIS OF CHRONIC LIVER INJURY**

Minisymposium

Mon. 8:30 AM–McCormick Place Convention Center, W179B

Chaired: T. Wu, L. Wang

**Liver Pathobiology**

**Inflammation**


8:45  **328.2** Increased Fibrosis and Ductular Reaction in Liver of Offspring Exposed to Maternal High Fat Diet. M.D. Thompson, M.J. Cismowski, L.K. Rogers, D.R. Brigstock. Nationwide Children's Hospital.

9:00  **328.3** High Fat Diet-Induced Biliary Lipopapoptosis, Senescence, Hepatic Steatosis and Fibrosis Are Reduced in Secretin Receptor Knockout (SR⁻⁻) Mice. L.L. Kennedy, N. Wu, J. Venter, F. Meng, H. Francis, T. Zhou, S. Glaser, G. Alpini. Texas A&M HSC, VA and Baylor S&W.

9:15  **328.4** A Novel Hepatocyte SHP/CCL2 Axis Controls Liver Inflammation in NAFL to NASH Transition. N.S. Magee. University of Kansas Medical Center.

9:30  **328.5** Activating β-Catenin Mutations and PI3KCA Synergize to Promote Lipogenic Liver Tumors in Mice. j. Tao, n. Zhan, s. Singh, x. Chen, p. Monga. University of Pittsburgh Medical Center and University of California San Francisco.


10:00 **328.7** Hepatic Fibrosis Is Independent of the Effects of Endotoxin (Lipopolysaccharide) on Hepatic Stellate Cells. C.R. Gandhi. Cincinnati Children's Hospital Medical Center.

10:30 **328.8** Smoothened Deficiency Accelerates Fas-Induced Liver Injury. W. Chen, Y. Wang, C. Han, J. Zhang, K. Song, H. Kwon, L. Yao, T. Wu. Tulane University School of Medicine, Tongji Medical School, People's Republic of China.


11:00 **328.10** Blocking the CCL2-CCR2 Axis Using CCL2 Neutralizing Antibody Is an Effective Therapy for Hepatocellular Cancer in a Mouse Model. K. Teng, J. Han, J. Yu, K. Ghoshal. The Ohio State University.